EpiCept Initiates Advanced Cancer Study
Posted on: Wednesday, 20 December 2006, 12:00 CST
EpiCept Corporation has initiated a phase I clinical study of EPC2407, for the treatment of patients with advanced solid tumors and lymphomas.
EPC2407 is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors include the frequently occurring cancers of the lung, gastrointestinal tract, ovaries, and breast. Despite encouraging progress in treating earlier stages of these diseases, these cancers continue to have high mortality rates in spite of some new classes of anti-tumor agents in recent years.
The phase I trial of EPC2407 will administer increasing doses to small groups in approximately 30 patients with advanced stages of solid tumors. The primary objectives of the study are to determine the safe doses and blood concentrations of the drug. The study will also characterize the pharmacodynamic effects on blood flow and identify early signs of anti-tumor response as measured by CT scans, MRI or PET, in these advanced cancer patients with well vascularized solid tumors. The trial is expected to last one year.
"EPC2407 is the second clinical cancer candidate discovered by EpiCept researchers using this apoptosis screening technology and we continue to seek other promising cancer compounds targeting markets of substantial size and large unmet medical needs," said Jack Talley, president and CEO.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation
- Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
- Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
- Breast Cancer Patients May Be Offered Chemo-Free Treatment
- Scottish Hospital to Offer Cancer Patients Advanced Radiotherapy Treatments With New Equipment and Software From Varian Medical Systems
- One-Day Radiation May Become an Option For Breast Cancer Patients
- Novel Lipoplex Nanoparticle to Be Used in First Human Trial Treating Advanced Solid Cancer
- Anti-Tumor Drug Extends Lung Cancer Patients' Lives
- Genentech's Drug, Avastin, Helped Cancer Patients Live Longer, Study Reveals
 |
 |
User Comments (0)
RSS Feeds